NCT01846351

Brief Summary

Study designed to evaluate the effect of significant ERM on the visual and anatomic outcomes of intravitreal anti-VEGF therapy for eAMD.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
16

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jul 2006

Typical duration for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2006

Completed
3.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2010

Completed
3.2 years until next milestone

First Submitted

Initial submission to the registry

May 1, 2013

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 3, 2013

Completed
Last Updated

May 3, 2013

Status Verified

May 1, 2013

Enrollment Period

3.6 years

First QC Date

May 1, 2013

Last Update Submit

May 1, 2013

Conditions

Epiretinal MembraneAge Related Macular Degeneration

Keywords

choroidal neovascularizationepiretinal membraneanti-VEGF

Outcome Measures

Primary Outcomes (3)

  • Best corrected visual acuity

    Evaluate the best visual acuity during the follow up.

    12 months

  • Central macular thickness

    Evaluation of the retinal thickness changes with anti-VEGF treatment

    12 months

  • Fluorescein angiogram

    Evaluation of changes in lesion size during follow-up.

    12 months

Eligibility Criteria

Age58 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

age-related macular degeneration

You may qualify if:

  • Significant epiretinal membrane
  • Anti-VEGF treatment for age-related macular degeneration

You may not qualify if:

  • Uveitis
  • Macular disorders
  • Diabetic retinopathy
  • Vascular occlusions

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Epiretinal MembraneMacular DegenerationChoroidal Neovascularization

Condition Hierarchy (Ancestors)

Retinal DiseasesEye DiseasesRetinal DegenerationChoroid DiseasesUveal DiseasesNeovascularization, PathologicMetaplasiaPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Nauman A Chaudhry, MD

    New England Retina Associates

    PRINCIPAL INVESTIGATOR

  • Peter E Liggett, MD

    New England Retina Associates

    STUDY CHAIR

Study Design

Study Type
observational
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

May 1, 2013

First Posted

May 3, 2013

Study Start

July 1, 2006

Primary Completion

February 1, 2010

Study Completion

February 1, 2010

Last Updated

May 3, 2013

Record last verified: 2013-05